🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  2. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  3. This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.

    Lacuna Pharma Pty Ltd

    Chronic Inducible Urticaria

    phase 1 other active

    1 trial

  4. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  5. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  6. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  7. ThisCART19A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial

  8. ThisCART19A with Dose Level 1

    The First People's Hospital of Lianyungang

    CAR

    phase 1 small molecule active

    1 trial

  9. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  10. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  11. To evaluate the pharmacokinetics and safety of nolasiban

    Novo Nordisk A/S

    not applicable (submitted trial is a pharmacokinetic study in healthy subjects)

    phase 1 other active

    1 trial

  12. Tolvaptan 15mg or 30mg or 60mg or Placebo

    Otsuka Beijing Research Institute

    Healthy

    phase 1 small molecule completed

    1 trial

  13. Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  14. Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial

    Lacuna Pharma Pty Ltd

    Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection

    phase 1 other active

    1 trial

  15. Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  16. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  17. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  18. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  19. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  20. Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants

    Lacuna Pharma Pty Ltd

    Clostridioides difficile (C. difficile)

    phase 1 other active

    1 trial

  21. Tuberculosis (TB) vaccine (Ad5-105K)

    CanSino Biologics

    Tuberculosis

    phase 1 mab active

    1 trial

  22. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  23. Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  24. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources